Medicines and Healthcare products Regulatory Agency (original) (raw)
Featured
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine sparsentan (Filspari) to treat primary immunoglobulin A nephropathy (IgAN).
Responses will help shape reforms that will boost UK patients’ access to safe and innovative medical products
This case study is an example of how the MHRA is benefiting from patients providing their lived experience for the pre-authorisation stage of the benefit-risk review.
The ninth annual #MedSafetyWeek takes place this week, with regulators from 94 countries and 107 organisations taking part across the globe.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 30 October, approved the medicine sugemalimab (Eqjubi) to treat adult patients with a type of lung cancer called ‘non-small cell lung cancer’.
The Medicines and Healthcare products Regulatory Agency (MHRA) is reminding healthcare professionals to ensure patients are aware of the known side effects of glucagon-like peptide-1 (GLP-1) receptor agonists.
Latest from the Medicines and Healthcare products Regulatory Agency
What we do
Follow us
Documents
Our management
Chief Healthcare Quality & Access Officer
Director of Communications and Engagement
Interim Executive Director, Science and Research
Interim Executive Director, Innovation and Compliance
Interim Executive Director Healthcare Quality and Access
Contact MHRA
Make an FOI request
- Read about the Freedom of Information (FOI) Act and how to make a request.
- Check our previous releases to see if we’ve already answered your question.
- Make a new request by contacting us using the details below.